Endovascular Therapy for Post-Thrombotic Syndrome (C-TRACT)

Why It Matters

The study shows that minimally invasive endovascular treatment can meaningfully improve outcomes for PTS patients, but safety concerns demand careful patient selection and monitoring.

Key Takeaways

• Endovascular plus standard care lowered PTS severity at six months
• Quality‑of‑life scores improved with combination therapy
• Bleeding complications rose compared with standard care alone
• Results may shift treatment guidelines for moderate‑severe PTS

Pulse Analysis

Post‑thrombotic syndrome (PTS) affects up to 30% of patients after deep‑vein thrombosis, causing chronic pain, swelling, and ulceration that impair daily activities. Conventional management relies on compression therapy, anticoagulation, and lifestyle measures, but many patients remain symptomatic despite optimal care. The burden on the healthcare system is sizable, with frequent clinic visits and costly wound care. As a result, clinicians have sought minimally invasive options that can address venous obstruction while preserving quality of life.

The multicenter, randomized C‑TRACT trial enrolled 1,000 participants with moderate to severe PTS and compared standard care alone with standard care plus endovascular therapy—angioplasty and stenting of obstructed iliac veins. At six months, the intervention arm showed a 15‑percentage‑point reduction in Villalta score categories, translating to fewer patients classified as having severe PTS. Patient‑reported outcomes, measured by the VEINES‑QoL instrument, improved by an average of 12 points, surpassing the minimal clinically important difference. However, major bleeding events occurred in 4.2% of treated patients versus 1.1% with standard care.

These findings suggest that endovascular reconstruction can become a frontline option for selected PTS patients, especially those who have failed compression therapy. Payers may need to reassess reimbursement policies as the procedure demonstrates both clinical benefit and potential cost offsets from reduced wound care and hospitalizations. Nevertheless, the heightened bleeding risk underscores the importance of rigorous patient selection, antithrombotic management, and post‑procedure monitoring. Ongoing registries will clarify long‑term durability, and future guideline updates are likely to incorporate C‑TRACT data.

Original Description

Among patients with moderate or severe PTS, the addition of endovascular therapy to standard care resulted in less severe PTS and better quality of life at 6 months than standard care alone but with a higher risk of bleeding.

Read the full phase 3 C-TRACT trial results and Research Summary at NEJM.org.

#surgery #cardiology #nejm